Arca Biopharma board approves reverse stock split prior to Oruka merger
Arca Biopharma's board of directors late last week approved a 1-for-12 reverse stock split in advance of the drug-discovery’s upcoming merger with Oruka Therapeutics Inc.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Arca Biopharma has completed its merger with Oruka Therapeutics Inc.
-
Enliven Therapeutics finished the third quarter with $292 million in cash, which, the company said,…
-
Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
